This content is not available in English

Health Sciences / Faculty /

Diana Laura Castillo Carranza

[email protected]
Departments
Medicina
Formación académica

Químico Farmacéutico Biólogo

Universidad Autónoma de Tamaulipas

Maestría en Ciencias con Orientación en Morfología

Universidad Autónoma de Nuevo León

Doctor en Ciencias con Orientación en Morfología

Universidad Autónoma de Nuevo León

Postdoctorado en Neurociencias

University of Texas Medical Branch (UTMB)

Trayectoria profesional y docente

Profesor Investigador

Universidad de Monterrey

2020-Actual

Assistant Professor

Hampton University, VA USA

2016 - 2019

Postdoctoral Fellow

University of Texas Medical Branch, UTMB

2009 - 2015

Profesor Investigador

Universidad de Monterrey

2006-2009

Docente Histología

Facultad de Medicina, UANL

2003-2004

ASESOR DE TESIS PEF – UDEM

  • 2023 Tesis: manifestaciones morfológicas y funcionales de la dieta hipercalórica administrada desde la etapa de lactancia hasta la vida adulta en ratones BALB/C
  • 2022 Tesis: Identificación de los efectos degenerativos asociados a una dieta hipercalórica en ratones
  • 2021 Tesis: Identificación de los efectos degenerativos asociados a una dieta hipercalórica y alta en grasas en ratones
Distinciones y premios
  • 2023 Investigador Nacional Nivel II (SNI II), Reingreso vigente Sistema Nacional de Investigadores periodo 2023-2027.
  • 2020 Investigador Nacional Nivel II Rei(SNI II), Reingreso vigente Sistema Nacional de Investigadores periodo 2019-2022.
  • 2019 Mentor distinguido otorgado por: the Governor’s School Science and Technology. Hampton, Virginia. USA.
  • 2018 Mentor distinguido otorgado por: the Governor’s School Science and Technology. Hampton, Virginia. USA.
  • 2018 Reconocimiento al trabajo de investigación publicado en la revista Biological Psychiatry 2018, Castillo-Carranza et al. Comentario escrito por el Prof. Jackson G, Biol Psy 2018, Lifestyles of a Toxic Twosome: A Novel Tau Strain Induced by a-Synuclein Oligomers”.
  • 2016 Beca otorgada por el Marine Biological Laboratory para atender al curso: Zebrafish Development and Genetics, Woods Hole, MA, USA.
  • 2016 Distinción como: “Early Career Investigator Travel Award” para atender al Keystone Symposia “Common Mechanisms of Neurodegeneration”, Keystone Co, USA.
  • 2015 Investigador Nacional Nivel I (SNI I), Sistema Nacional de Investigadores (SNI) periodo 2015-2018.
  • 2014 Premio al mejor trabajo de la University of Texas Medical Branch, otorgado por el Sealy Center for Vaccine Development (SCVD), para su presentación en el 8th Annual International Society of Vaccine Congress in PA USA.
  • 2012 Investigador Nacional Nivel I (SNI I), Sistema Nacional de Investigadores (SNI) periodo 2012-2014.
  • 2010 Beca Postdoctoral otorgada por la University of Texas Medical Branch y la Escuela de Graduados en Ciencias Biomédicas, verano del 2010.
  • 2009 Beca del Consejo Nacional de Ciencia y Tecnología, CONACYT, para realizar estancia Postdoctoral en el Extranjero en la categoría de Consolidación de Grupos de Investigación. UTMB, Galveston Texas, USA.
  • 2006 Doctorado en Ciencias con Orientación en Morfología, (Cum Laude). Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.
  • 2004 Reconocimiento como Estudiante distinguido del Programa de Doctorado en Ciencias. Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México
  • 2002 Beca del Consejo Nacional de Ciencia y Tecnología, CONACYT, para obtener el grado de Doctor en Ciencias. UANL, Monterrey, Nuevo León, México.
  • 2002 Mención Honorífica, Maestría en Ciencias con Orientación en Morfología.
  • 2001 Beca otorgada por The IBRO School for Neurosciences para asistir al curso “Cellular and Molecular Biology of Neural Development”. Center of Neurobiology, UNAM, Juriquilla Queretaro, México.
  • 1999 Beca del Consejo Nacional de Ciencia y Tecnología para obtener el grado de Mestro en Ciencias. Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.
Publicaciones
  • 1. Jackson N, Guerrero-Munoz MJ, Castillo-Carranza DL., The prion-like transmission of tau oligomers via exosomes. Front Aging Neurosci 2022
  • 2. Castillo-Carranza DL., A toxic subset of soluble α-synuclein species in dementia with Lewy body. Brain Commun. 2020
  • 3. Gerson JE, Farmer KM, Henson N, Castillo-Carranza DL, Carretero-Murillo M, Sengupta M, Barret A, Kayed R. Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy. Molecular Neurodegeneration, 2018.
  • 4. Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, Gerson JE, Kayed R. α-synuclein oligomers induce a unique toxic tau strain. Biological Psychiatry 2018.
  • 5. Castillo-Carranza DL, Nilson AN, Van Skike CE, Jahrling JB, Patel K, Garach P, Gerson JE, Sengupta U, Abisambra J, Nelson P, Troncoso J, Ungvari Z, Galvan V, Kayed R. Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related Tauopathies. Aging Dis. 2017
  • 6. Shafiei SS, Guerrero-Muñoz MJ, Castillo-Carranza DL. Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. Front Aging Neurosci. 2017
  • 7. Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, Zetterberg H, Galasko D, Blennow K, Kayed R. Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Ann Clin Transl Neurol. 2017.
  • 8. Nilson AN, English KC, Gerson JE, Whittle TB, Crain CN, Xue J, Sengupta U, Castillo-Carranza DL, Zhang W, Gupta P, Kayed R. Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases.JAD 2017.
  • 9. Gerson JE, Castillo-Carranza DL, Sengupta U, Bodani R, Prough DS, DeWitt D, Hawkins BE, Kayed R. Tau oligomers derived from Traumatic Brain Injury cause cognitive impairment and accelerate onset of pathology in Htau mice. Neurotrauma. 2016 Jan 5.
  • 10. Guerrero-Muñoz MJ, Gerson JE, Castillo-Carranza DL. Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease. Front. Cell. Neurosci, 02 December 2015. http://dx.doi.org/10.3389/fncel.2015.00464
  • 11. Bodani RU, Sengupta U, Castillo-Carranza DL, Guerrero-Muñoz MJ, Gerson JE, Rudra J, Kayed R. Antibody against Small Aggregated Peptide Specifically Recognizes Toxic Aβ-42 Oligomers in Alzheimer's Disease. ACS Chem Neurosci. 2015 Dec 16;6(12):1981-9 doi: 10.1021/acschemneuro.5b00231.
  • 12. Castillo-Carranza DL, Guerrero-Munoz MJ, Sengupta U, Hernandez C, Barret A, Dineley KT, Kayed R. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an AD mouse model. JNS, 25 March 2015, 35(12): 4857-4868. doi: 10.1523/JNEUROSCI.4989-14.2015
  • 13. Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen A, Jackson JR, Kayed R. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biological Psychiatry. 2014. doi:10.1016/ j.biopsych.2014.12.019
  • 14. Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R. Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles. J Neurosci. 2014 Mar 19;34(12):4260-72. Doi: 10.1523/JNEUROSCI.3192-13.2014.
  • 15. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Kayed R. Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds. J Alzheimers Dis. 2014.
  • 16. Guerrero-Munoz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen A, Sengupta U, Lasagna-Reeves CA, Jackson GR, Kayed R. Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer’s disease. Neurobiology of Disease. 2014, 71:14-23.
  • 17. Gerson JE, Castillo-Carranza DL, Kayed R. Advances in Therapeutics for Neurodegenerative Tauopathies: Moving Towards the Specific Targeting of the Most Toxic Tau Species. ACS Chem Neurosci. 2014 Jul 30
  • 18. Guerrero-Muñoz MJ, Castillo-Carranza DL, Kayed R. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem Pharmacol. 2014 Jan 6. Doi: 10.1016/j.bcp.2013.12.023
  • 19. Lasagna-Reeves C, Sengupta U, Castillo-Carranza D, Gerson J, Guerrero-Munoz MJ, Jackson GR, Kayed R. The formation of tau pore-like structures in tauopathies is prevalent and cell specific: Possible implications for the disease phenotypes. Acta Neuropathol Commun. 2014 May 29;2(1):56. doi: 10.1186/2051-5960-2-56.
  • 20. Guerrero-Muñoz MJ, Castillo-Carranza DL, Sengupta U, White MA, Kayed R. Design of Metastable β-Sheet Oligomers from Natively Unstructured Peptide. ACS Chem Neurosci. 2013 Dec 18. doi: 10.1021/cn4001395
  • 21. Hawkins BE*, Krishnamurthy S*, Castillo-Carranza DL*, Sengupta U, Prough DS, Jackson GR, Dewitt DS, Kayed R. Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury: Possible Link Between TBI and Sporadic Tauopathies. J Biol Chem. 2013 Apr 30. Note: *Contributed equally. doi: 10.1074/jbc.M113.472746.
  • 22. Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R. Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?. ImmunoTargets and Therapy. Dec 2013. DOI: http://dx.doi.org/10.2147/ITT.S40131
  • 23. Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R. Tau aggregates as immunotherapeutic targets. Front Biosci (Schol Ed). 2013 Jan 1;5:426-38. DOI No:10.2741/S38
  • 24. Lasagna-Reeves CA, Clos AL, Castillo-Carranza D, Sengupta U, Guerrero-Muñoz M, Kelly B, Wagner R, Kayed R. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. Biochem Biophys Res Commun. 2013 Jan 18;430(3):963-8. doi: 10.1016/j.bbrc.2012.11.130
  • 25. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R.Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2012;2:700. doi: 10.1038/srep00700
  • 26. Castillo-Carranza DL, Zhang Y, Guerrero-Muñoz MJ, Kayed R, Rincon-Limas DE, Fernandez-Funez P.Differential activation of the ER stress factor XBP1 by oligomeric assemblies. Neurochem Res. 2012 Aug;37(8):1707-17. doi: 10.1007/s11064-012-0780-7.
  • 27. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 2012 Jan 17. doi: 10.1096/fj.11-199851
  • 28. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2011 Sep;8(6):659-65.
  • 29. Clos AL, Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Jackson GR, Kelly B, Beachkofsky TM, Kayed R. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis. Br J Dermatol. 2011 Dec;165(6):1349-54. doi: 10.1111/j.1365-2133.2011.10508.x
  • 30. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener. 2011 Jun 6;6:39 doi: 10.1186/1750-1326-6-39.
  • 31. Lasagna-Reeves, Diana L. Castillo-Carranza, Marcos J. Guerrero-Muñoz, George R. Jackson, Rakez Kayed. Preparation and Characterization of Neurotoxic Tau Oligomers. Biochemistry 2010, 10039–10041. doi: 10.1021/bi1016233
  • 32. Castillo-Carranza DL, Rodríguez-Rocha H, Montes-de-Oca-Luna R, Sepúlveda-Saavedra J, Martínez HR, López-Vidal Y, Saucedo-Cárdenas O. Pitx3 promoter directs Cre-recombinase specifically in a human neuroblastoma cell line”. Mol Cell Biochem. 309:223–227. 2008.


ABSTRACTS PUBLICADOS:

  • 1. K Berland, JE Padilla-Muñoz, MJ Guerrero-Muñoz, DL Castillo-Carranza, Alpha-synucleina potencia la toxicidad de oligomeros de tau en células de neuroblastoma; Revista de Ciencias Farmaceúticas y Biomedicina (ISSN: 2448-8380), 16; 2020
  • 3. Kayed R, Sengupta U, Gerson J, Hasan J, Carretero-Murillo M, Castillo-Carranza DL. Potential role of oligomeric tau strains in the pathogenesis of synucleinopathies. Journal of the Neurological Sciences, Supplement, October 2017, Vol 381, Page 84.
  • 4. Kayed R, Gerson J, Farmer K, Castillo-Carranza DL, Sengupta U. Intersection of alpha-synuclein and tau neurotoxicity in neurodegenerative disease. ANNALS OF NEUROLOGY, Supplement, November 2017, Vol 82, Pages S-147-S147.
  • 5. Castillo-Carranza DL, Gerson J, Sengupta U, Dineley K, Barrett A, Kayed R. Preclinical studies targeting toxic oligomers by immunotherapy. ANNALS OF NEUROLOGY, Supplement, November 2016, Vol 80, Pages S-182-S182.
  • 6. Nilson A, English K, Gerson J, Farmer K, Sengupta U, Castillo-Carranza DL, Masel T, Kayed R. Tau oligomers and inflammation: their association and implications for spreasing and therapy. Alzheimer's & Dementia, Volume 12, Issue 7, Supplement, July 2016, Pages P1046.
  • 7. Gerson J, Sengupta U, Castillo-Carranza DL, Guerrero-Muñoz MJ, Masel T, Kayed R. Tau oligomers as a mediator of toxicity in mixed protein pathology diseases. Alzheimer's & Dementia, Volume 12, Issue 7, Supplement, July 2016, Pages P467.
  • 8. Gerson J, Sengupta U, Farmer K, Castillo-Carranza DL, Nilson A, Henson N, Masel T, Barret A, Kayed R. Altering the trajectory of synuceinopathies by targeting downstream toxicity of tau oligomers. Alzheimer's & Dementia, Volume 12, Issue 7, Supplement, July 2016, Pages P391-P392.
  • 9. Gerson J, Castillo-Carranza DL, Sengupta U, Henson N, Nilson A, Kayed R. Tau oligomer antibodies as potential therapeutics for parkinson’s and other synucleinoppathies. Journal of the Neurological Sciences, 2015, Vol 357, Pages e10.
  • 10. Gupta P, Castillo-Carranza DL, Whittle B, Crain N, Paulucci A, Godley BF, Gerson J, Sengupta U, Kayed R. Tau oligomers trigger inflammation in the eyes of the Alzheimer’s disease mouse models. Investigative Ophthalmology & Visual Science, Supplement, June 2015, Vol 56Pages 855-855.
  • 11. Castillo-Carranza DL, Guerrero-Muñoz MJ, Farhed M, Sengupta U, Krishnamurthy S, Kayed R. Oligomers of a-synuclein cross-seed tau and extend lifetime of tau toxic conformation. Alzheimer's & Dementia, Volume 10, Issue 4, Supplement, July 2014, Pages P345. doi:10.1016/j.jalz.2014.05.359
  • 12. Guerrero-Muñoz M, Castillo-Carranza D, Krishnamurthy S, Kayed R. TDP-43 hybrid oligomers in Alzheimer's disease. Alzheimer’s & Dementia, Volume 10, Issue 4, Supplement, July 2014, Page P651. doi:10.1016/j.jalz.2014.05.1154
  • 13. Gerson JE, Castillo-Carranza D, Sengupta U, Kayed R. Tau oligomers derived from traumatic brain injury cause toxicity and cognitive impairment in Htau mice. Alzheimer’s & Dementia, Volume 10, Issue 4, Supplement, July 2014, Page P146. doi:10.1016/j.jalz.2014.04.103
  • 14. Castillo-Carranza D, Guerrero-Muñoz M, Sengupta U, Krishnamurthy S, Hernandez C, Dineley K, Jackson G, Kayed R. Reduction of tau oligomers by immunotherapy improves cognition in an Alzheimer’s disease mouse model. Alzheimer's & Dementia, Volume 9, Issue 4, Supplement, July 2013, Pages P325-P326. doi:10.1016/j.jalz.2013.04.165
  • 15. Castillo-Carranza D, Guerrero-Muñoz M, Sengupta U, Krishnamurthy S, Gerson J, Dineley K, Jackson G, Kayed R. Specific targeting of tau oligomeric seeds by passive immunization. Alzheimer's & Dementia, Volume 9, Issue 4, Supplement, July 2013, Page P330. doi:10.1016/j.jalz.2013.04.178
  • 16. Guerrero-Muñoz M, Castillo-Carranza D, Lasagna-Reeves C, Sengupta U, Krishnamurthy S, Jackson G, Kayed R. Formation of toxic oligomeric species from different proteins in Alzheimer's disease: Potential toxic interactions at the oligomer aggregation stage. Alzheimer's & Dementia, Volume 9, Issue 4, Supplement, July 2013, Page P305. doi:10.1016/j.jalz.2013.05.631
  • 17. Sengupta U, Portelius E, Castillo-Carranza D, Woltjer R, Galasko D, Jackson G, Blennow K, Kayed R. Tau oligomers in CSF: a novel biomarker for the diagnosis and evaluation of treatment for Alzheimer's disease and Tauopathies., Alzheimer's & Dementia, Vol.9, Issue 4, Supplement, July 2013, Page 356. doi:10.1016/j.jalz.2013.08.190
  • 18. Castillo-Carranza D, Lasagna-Reeves C, Guerrero-Munoz M, Sengupta U, Barrett A, Dineley K, Jackson G, Kayed R. Specific clearance of tau oligomers by passive immunization. Alzheimer's & Dementia, Volumen 8, Issue 4, Supplement, 2012, Pag.624-625. doi:10.1016/j.jalz.2012.05.1664
  • 19. Castillo-Carranza DL, Lasagna-Reeves CA, Guerrero-Munoz MJ, Estes D, Barrett A, Dineley K, Jackson G, Kayed R. Modulation of tau oligomers by passive vaccination. The SFN 40th annual meeting, 2010, San Diego, CA. Featured in Neurology today and AlzForum: http://www.alzforum.org/new/detail.asp?id=2617
  • 20. Castillo-Carranza DL, Lasagna-Reeves CA, Gurrero-Muñoz MJ, Jackson G, Troncoso J, Kayed R. Alpha-synuclein oligomers in Parkinson’s disease (PD) and lewy body dementia (DLB). Movement Disorders. 2010;25:S181-S565. DOI: 10.1002/mds.23162
  • 21. C. A. Lasagna-Reeves B. Roi, M. J. Guerrero-Muñoz, D. L. Castillo-Carranza, J. Troncos, R. Kayed, G. R. Jackson. Role of Tau oligomers in Parkinson's disease and dementia with Lewy bodies. Movement Disorders. 2010;25: S181-S565. DOI: 10.1002/mds.23162
Presencia en congresos
  • 1. Castillo-Carranza DL; Title: “Alzheimer’s disease: A prion-like disorder”. BIO425 Research Seminar Series Spring 2017.
  • 2. Castillo-Carranza DL, Guerrero-Muñoz MJ, Brown-Hughes Travonia, Heyliger S. Development of Alzheimer’s/Dementia Research Capacity and Center at HU. Researcher’s Informational Forum, 2016.
  • 3. Castillo-Carranza DL*, Guerrero-Muñoz MJ, Sengupta U, Shafiei S, Gerson J, Hawkins B, Kayed R. Potential role of exosomal tau and alpha-synuclein oligomers in cell toxicity and spreading pathology in PD and DLB. The Society for Neuroscience, 2015.
  • 4. *Gerson J, Castillo-Carranza DL*, Sengupta U, Henson N, Nilson A, Kayed R. Targeting the toxic synergy of α-synuclein and tau with tau oligomer-specific antibodies. The Society for Neuroscience, 2015.
  • 5. Castillo-Carranza DL*. Intersection of α-Synuclein seeds and Tau augment propagation and neurotoxicity. George P. and Cynthia Mitchell center for neurogenerative disease, seminar series, UTMB, Galveston TX, June, 2015
  • 6. Castillo-Carranza DL*. Removal of tau oligomers by immunotherapy ameliorate memory in an Alzheimer’s disease mouse model. 8th Vaccine ISV Congress, Philadelphia PA, USA, 2014.
  • 7. Gerson JE*, Castillo-Carranza DL, Sengupta U, Lasagna-Reeves CA, Kayed R. Tau oligomers from Alzheimer's disease and Traumatic Brain Injury induce toxicity in Htau mice. Society for Neuroscience Conference (SfN), Washington DC, USA, Nov 2014. * Selected to present at Neuroscience 2014 press conference and as a Neuroscience 2014 Hot Topic.
  • 8. Gerson JE, Castillo-Carranza DL, Sengupta U, Kayed R. Tau Oligomers derived from Traumatic Brain Injury cause toxicity and cognitive impairment in Htau mice. Alzheimer’s Association International Conference (AAIC), Copenhagen, Denmark. Alzheimer’s & Dementia, 10, 4, 146, 2014.
  • 9. Gerson JE, Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Kayed R. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau pathology following injection with brain-derived tau oligomeric seeds. 18th Annual Neuroscience Symposium, University of Texas, Austin, TX, 2014.
  • 10. Castillo-Carranza DL*. Reduction of tau oligomers by immunotherapy improves cognition in an Alzheimer’s disease mouse model. Alzheimer Association International Conference (AAIC) 2013, Boston, Massachusetts. Castillo-Carranza DL*. Tau Oligomers a potential therapeutic target for tauopathies George P. and Cynthia Mitchell center for neurogenerative disease, seminar series, UTMB, Galveston TX, November, 2013
  • 11. Castillo-Carranza DL, Guerrero-Muñoz M, Sengupta U, Krishnamurthy S, Gerson J, Dineley K, Jackson G, Kayed R*. Specific targeting of tau oligomeric seeds by passive immunization. Alzheimer Association International Conference (AAIC), Boston, Massachusetts. 2013
  • 12. Castillo-Carranza DL*. Tau oligomers as a novel target for passive immunotherapy. George P. and Cynthia Mitchell center for neurogenerative disease, seminar series, UTMB, Galveston TX, November, 2012.
  • 13. Kayed R*, Castillo-Carranza DL, Gerson J, Guerrero-Munoz MJ, Sengupta U. Systematic administration of tau oligomer-specific antibody averts tauopathy phenotypes in two different animal models. Society for Neuroscience 2012, San Diego CA.
  • 14. Kayed R*, Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kkiritoshi T, Neugebauer V, Jackson G. Tau pathology initiated by brain-derived soluble tau oligomeric seeds. Society for Neuroscience 2012, San Diego CA.
  • 15. Castillo-Carranza DL*. Specific Reduction of tau oligomers by passive immunization reversed the phenotypes in AD mouse models”. George P. and Cynthia Mitchell center for neurogenerative disease, seminar series, UTMB, Galveston TX, October 2011.

 

PRESENTACION DE POSTERS

  • 1. Diana L. Castillo Carranza, Jorge Padilla Munoz, Shavontay Tate, Kayla Ingram, Luisel Ricks-Santi y Marcos Guerrero-Munoz. Conformaciones toxicas de alfa sinucleina en sistemas de dos fases. Vl Simposio Nacional de Ciencias Farmacéuticas y Biomedicina y lV Simposio Nacional de Microbiología Aplicada. Universidad Autónoma de Nuevo León. 4 de Abril, 2019.
  • 2. Ciara Crossa, Arely Gonzalez, Diana L. Castillo Carranza, Marcos Guerrero-Munoz. Expresión de alfa sinucleína recombinante en dos estados conformacionales. Vl Simposio Nacional de Ciencias Farmacéuticas y Biomedicina y lV Simposio Nacional de Microbiología Aplicada. Universidad Autónoma de Nuevo León. 4 de Abril, 2019
  • 3. Katelynne Berland, Kevin Simental, Marcos Guerrero-Munoz, Diana L. Castillo Carranza. Alfa sinucleína potencia la toxicidad de oligómeros de tau en células de neuroblastoma Vl Simposio Nacional de Ciencias Farmacéuticas y Biomedicina y lV Simposio Nacional de Microbiología Aplicada. Universidad Autónoma de Nuevo León. 4 de Abril, 2019
  • 4. Jackson N, Guerrero-Munoz M, Castillo-Carranza DL. Unconventional Protein Secretion As a Mechanism for the Aggregation of α-Synuclein and Tau Oligomers. SACNAS, San Antonio TX, 2018.
  • 5. Ingram K., Wiafe E., Forbes B., Lewter T., Tate S., Guerrero-Munoz MJ., Castillo-Carranza DL. Mechanism of toxicity mediated by the interplay of tau, amyloid-B and a-synuclein. Neuroscience 2017, Washington DC, November 11th, 2017.
  • 6. Castillo-Carranza DL ., Tate S., Ingram K., Ricks-Santi L., Guerrero-Munoz MJ., In vitro compartmentalization accelerates the formation of toxic alpha-synuclein protein aggregates. Neuroscience 2017, Washington DC, November 11th, 2017.
  • 7. Kayed R, Sengupta U, Carretero-Murillo M, Castillo-Carranza DL, Gerson J. Differential spreading and toxicity of brain-derived tau oligomeric stains. Neuroscience 2017, Washington DC, November 11th, 2017.
  • 8. Sengupta U, Gerson J, Castillo-Carranza DL, Kayed R. The role of alpha-synuclein oligomeric conformations on tau aggregation and the formation of oligomeric strains. Neuroscience 2017, Washington DC, November 11th, 2017.
  • 9. Kayed R, Gerson JE, Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ. Toxic synergy between amyloid aggregates in disease and their role in tau oligomeric strain formation. Neuroscience 2016. San Diego, CA, November 16th, 201
  • 10. Farmer K, Lasagna-Reeves CA, Clos A, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kelly B, Wagner R, Kayed R. The aggregation of p53 oligomers in cancer and neurodegenerative disease. Galveston, Tx. The 20th Annual Forum on Aging. October 20th, 2016
  • 11. Castillo-Carranza DL, Guerrero-Muñoz MJ, Sengupta U, Gerson JE, Samuel R, Kayed R. Keystone Symposia “Common Mechanisms of Neurodegeneration”, Keystone Co, USA, 2016.
  • 12. Kayed R, Castillo-Carranza DL, Gerson JE, Guerrero-Muñoz MJ, Sengupta U, Hawkins BE, Barrett A, The specific targeting of tau oligomers therapeutically in Alzheimer’s disease J. E. The Society for Neuroscience, 2015.
  • 13. Hawkins BE, Gerson JE, Sengupta U, Castillo-Carranza DL, Prough DS, Dewitt DS, Kayed R. Tau oligomers and traumatic brain injury: toxicity and potential drug targets. The Society for Neuroscience, 2015.
  • 14. Castillo-Carranza DL, Sengupta U, Shafiei S, Garach P, and Kayed R. Alzheimer's Association - Houston & Southeast Texas Chapter's 9th Annual Research Symposium on Alzheimer's Disease and Related Dementias, 2015.
  • 15. Castillo-Carranza DL*, Guerrero-Muñoz MJ, Farhed M, Sengupta U, Krishnamurthy S, Kayed R. Oligomers of α-synuclein cross-seed tau and extend lifetime of tau toxic conformation. Alzheimer’s Association International Conference (AAIC), Copenhagen, Denmark. Alzheimer's & Dementia, 10, 4, 345, 2014.
  • 16. Guerrero-Muñoz MJ, Castillo-Carranza DL, Krishnamurthy S, Kayed R. TDP-43 hybrid oligomers in Alzheimer’s disease. Alzheimer’s Association International Conference (AAIC), Copenhagen, Denmark. Alzheimer’s & Dementia, 10, 4, 651, 2014.
  • 17. Castillo-Carranza DL*, Guerrero-Munoz MJ, Krishnamurthy S, Sengupta U, Kayed R. Synergic toxic effect of alpha-synuclein and tau oligomers. Keystone symposia, 2014: Alzheimer’s disease Meeting– from Fundamental Insights to Light at the End of the Translational Tunnel (Q8). Keystone Co. 2014
  • 18. Guerrero-Munoz MJ*, Castillo-Carranza DL, Lasagna-Reeves CA, Krishnamurthy S, Dineley K, Jackson GR, Kayed R. Co-existence of oligomers from different amyloid proteins suggest that anti-Aβ therapeutic approaches may be insufficient to stop Alzheimer’s disease. Keystone symposia, 2014: Alzheimer’s disease Meeting– from Fundamental Insights to Light at the End of the Translational Tunnel (Q8). Keystone Co. 2014
  • 19. Gerson JE*, Sengupta U, Castillo-Carranza DL, Guerrero-Munoz MJ, Kayed R. Tau oligomers as a novel immunotherapeutic target for Parkinson’s disease and Lewy Body Dementia. Clinical and Translational Research Forum, Galveston, TX, 2014.
  • 20. Gerson J*, Sengupta U, Castillo-Carranza DL, kayed R. Tau internalization and toxicity depends upon the tau species and can be prevented by tau-oligomer specific antibodies. The Society for Neuroscience, 2013.
  • 21. Castillo-Carranza DL*, Guerrero-Muñoz MJ, Sengupta U, Singh G, Barrett A, Dineley K, Kayed R. Tau oligomers: A potential therapeutic target for Tauopathies. 17th Annual Forum on Aging Poster Session. November 2013.
  • 22. Castillo-Carranza DL*, Lasagna-Reeves CA, Guerrero-Muñoz MJ, Sengupta U, Estes M, Barrett AD, Dineley KT, Jackson GR, Kayed R. Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes The Society for Neuroscience (SFN 40th), New Orleans, LA. 2012
  • 23. Guerrero-Munoz MJ*, Castillo-Carranza DL, Lasagna-Reeves CA, Krishnamurthy S, Dineley K, Jackson GR, Kayed R. Modulation of Aβ oligomers in the Tg2576 Alzheimer’s disease mouse model by a novel generic anti-oligomer specific antibody. Society for Neuroscience, New Orleans, LA. 2012
  • 24. Sengupta U*, Lasagna-Reeves C, Guerrero-Munoz M, Castillo-Carranza D, Troncoso J, Jackson G, Kayed R. Oligomeric protein aggregates in Parkinson’s disease and other synucleinopathies. Society for Neuroscience, New Orleans, LA. 2012
  • 25. Castillo-Carranza DL*, Lasagna-Reeves CA, Guerrero-Muñoz MJ, Sengupta U, Singh Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R. Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotype. 16th Annual Forum on Aging Poster Session. November 2012.
  • 26. Guerrero-Muñoz MJ*, Castillo-Carranza DL, Lasagna-Reeves CA, Sengupta U, Krishnamurthy S, Hernandez C, Dineley K, Jackson G, Kayed R. Modulation of Aβ oligomers in the Tg2576 Alzheimer’s disease mouse model by a novel generic anti-oligomer specific antibody 16th Annual Forum on Aging Poster Session. November 2012.
  • 27. Sengupta U*, Castillo-Carranza DL, Barret AD, Portelius E, Blennow K, Jackson GR, Kayed R. Tau oligomers: Tool for diagnosis and evaluation of passive immunotherapy for Alzheimer’s disease. The Changing Landscape of Vaccine Development: Vaccines for Chronic Diseases, Symposium. Galveston. February 7-9, 2012.
  • 28. Guerrero-Munoz MJ*, Castillo-Carranza DL, Lasagna-Reeves CA, Sengupta U, Krishnamurthy S, Hernandez C, Dineley K, Jackson GR, Kayed R. Modulation of Aβ oligomers in the Tg2576 Alzheimer’s disease mouse model by a novel generic anti-oligomer specific antibody. The Changing Landscape of Vaccine Development:Vaccines for Chronic Diseases, Symposium. Galveston. February 7-9, 2012.
  • 29. Lasagna-Reeves CA*, Guerrero-Muñoz MJ, Castillo-Carranza DL, Sengupta U, Jackson GR, Troncoso JC, Kayed R. Crosstalk between alpha-synuclein and tau at the oligomer aggregation stage. Keystone symposium, Neurodegenerative diseases: The molecular and cellular pathway for neurodegeneration, Taos New Mexico, February 21-26, 2011.
  • 30. Lasagna-Reeves CA*, Roi B, Guerrero-Muñoz MJ, Castillo-Carranza DL, Kayed R, Jackson GR. Role of Tau oligomers in Parkinson’s disease (PD) and Lewy body dementia (DLB). 14th International Congress of Parkinson’s disease and Movement Disorders. Buenos Aires, Argentina, June 13-17, 2010. (Highlighted during the Blue Ribbon Session).
  • 31. Castillo-Carranza DL*, Lasagna-Reeves C, Guerrero-Muñoz MJ, Troncoso J, Jackson GR, Kayed R. Alpha-synuclein oligomers in Parkinson’s disease (PD) and Lewy body dementia (DLB). 14th International Congress of Parkinson’s disease and Movement Disorders. Buenos Aires, Argentina, June 13-17, 2010.
  • 32. Castillo-Carranza D*, Lasagna-Reeves CA, Guerrero-Muñoz MJ, Estes DM, Barret A, Dineley K, Jackson GR, Kayed R. Modulation of tau oligomers by passive vaccination. Society for Neurosciences annual meeting, San Diego CA, November, 2010. Featured at AlzForum: http://www.alzforum.org/new/detail.asp?id=2617
  • 33. Lasagna-Reeves CA*, Castillo-Carranza DL, Sengupta U, Clos AL, Kayed R. Cellular mechanism involved in tau oligomers neurotoxicity. Society for Neurosciences annual meeting, San Diego CA, November, 2010. Featured at AlzForum: http://www.alzforum.org/new/detail.asp?id=2617
  • 34. Sengupta U*, Lasagna-Reeves CA, Guerrero-Muñoz M, Castillo-Carranza D, Jackson GR, Troncoso JC, Kayed R. Tau oligomers in Parkinson disease and dementia with Lewy bodies and their connection with alpha synuclein oligomers. The Society for Neurosciences annual meeting, San Diego CA, November, 2010.
  • 35. Castillo-Carranza D*, Lasagna-Reeves C, Jackson GR, Kayed R. Induction of protein aggregation by preformed amyloid oligomers. 13th Annual Forum on Aging, organized by the Sealy Center on Aging at UTMB, November 12th 2009.


 

SNI
  • 2023-27 Investigador Nacional Nivel II , Reingreso vigente SNI
  • 2019 - 22 Investigador Nacional Nivel II, Reingreso vigente SNI
  • 2015- 18 Investigador Nacional Nivel I, Reingreso vigente SNI
  • 2012- 14 Investigador Nacional Nivel I, Ingreso SNI